Arcus Biosciences (RCUS) Preferred Stock Liabilities (2016 - 2017)
Arcus Biosciences (RCUS) recorded quarterly Preferred Stock Liabilities of $226.2 million in Q4 2017, up 89.36% quarter-over-quarter from $119.5 million in Q4 2016, and up 89.36% on a YoY basis from $119.5 million in Q4 2016.
Arcus Biosciences (RCUS) Preferred Stock Liabilities (2016 - 2017) Analysis & Trends
Arcus Biosciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $226.2 million for Q4 2017.
- In Q4 2017, Preferred Stock Liabilities rose 89.36% year-over-year to $226.2 million; the TTM figure through Dec 2017 stood at $226.2 million (up 89.36% YoY), while the FY2017 annual figure was $226.2 million, up 89.36% from the prior year.
- Preferred Stock Liabilities was $226.2 million for Q4 2017 at Arcus Biosciences, up from $119.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $226.2 million in Q4 2017 to a low of $119.5 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 226.20 Mn |
| Dec 31, 2016 | 119.45 Mn |